Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CEL-SCI Corporation (CVM)
USD1.15
+0.00 (+0.00%)
US AMEX Healthcare Biotechnology
Address
8229 Boone Boulevard 22182
Vienna, VA, US
Vienna, VA, US
CEO
Geert R. Kersten
Website
cel-sci.com
IPO
1983-12-08
CIK 725363 ISIN US1508377066
Description
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.15
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
455.2K
Beta
0.60
Float Shares
6.31M
Free Float %
91.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +10.00% | -17.82% | -71.11% | -70.08% | -78.00% | -72.81% | -80.14% | -98.53% | -99.79% | -99.71% | -99.95% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
1.15
DCF (Unlevered)
0.21
-81.5%
DCF (Levered)
0.39
-66.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-43.65
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+53.6% ★ Q1'26: +71.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-172.1% Q1'26: -0.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+103.9% Q1'26: +188.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.45× Q1'26: -487.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Sep 2015 actual |
Sep 2016 actual |
Sep 2017 actual |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 1 Rev. Ana. 1 EPS Ana. |
Sep 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
657.4K
est: 200.0K (+228.7%)
|
285.1K
est: 1.00M (-71.5%)
|
69.0K
est: 100.0K (-31.0%)
|
476.6K
est: 500.0K (-4.7%)
|
462.8K
est: 500.0K (-7.4%)
|
558.7K
est: 600.0K (-6.9%)
|
—
est: 100.0K (-100.0%)
|
—
est: 260.0K (-100.0%)
|
—
est: 9.13M (-100.0%)
|
4.69M
4.69M – 4.69M
-48.7% YoY
|
18.98M
18.98M – 18.98M
+304.7% YoY
|
| EBITDA |
-32.73M
est: 120.0K (-27,373.3%)
|
-9.08M
est: 600.0K (-1,613.5%)
|
-9.70M
est: 60.0K (-16,263.5%)
|
-16.12M
est: 300.0K (-5,474.0%)
|
-19.70M
est: 300.0K (-6,667.9%)
|
-27.06M
est: 360.0K (-7,616.6%)
|
-34.71M
est: 60.0K (-57,955.0%)
|
-22.21M
|
-20.88M
|
—
— – —
|
—
— – —
|
| EBIT |
-33.45M
est: 120.0K (-27,973.7%)
|
-24.75M
est: 600.0K (-4,224.5%)
|
-21.41M
est: 60.0K (-35,778.9%)
|
-16.77M
est: 300.0K (-5,690.7%)
|
-20.34M
est: 300.0K (-6,879.1%)
|
-29.22M
est: 360.0K (-8,216.5%)
|
-35.21M
est: 60.0K (-58,786.7%)
|
-26.17M
|
-24.76M
|
—
— – —
|
—
— – —
|
| Net Income |
-34.67M
est: -21.38M (-62.2%)
|
-11.47M
est: -432.53M (+97.3%)
|
-14.36M
est: -68.01M (+78.9%)
|
-31.84M
est: -56.68M (+43.8%)
|
-24.69M
est: -38.18M (+35.3%)
|
-32.22M
est: -45.94M (+29.9%)
|
-39.19M
est: -47.13M (+16.9%)
|
-26.92M
est: -80.30M (+66.5%)
|
-25.41M
est: -18.29M (-38.9%)
|
-16.87M
-16.87M – -16.87M
+7.8% YoY
|
-3.73M
-3.73M – -3.73M
+77.9% YoY
|
| SGA |
13.80M
est: 998.0K (+1,282.6%)
|
6.49M
est: 4.99M (+30.0%)
|
5.80M
est: 499.0K (+1,062.4%)
|
7.85M
est: 2.49M (+214.6%)
|
8.00M
est: 2.49M (+220.6%)
|
11.70M
est: 2.99M (+290.9%)
|
13.09M
est: 499.0K (+2,522.4%)
|
4.22M
|
5.04M
|
—
— – —
|
—
— – —
|
| EPS |
-268.80
est: -10.75 (-2,400.5%)
|
-62.70
est: -217.50 (+71.2%)
|
-1,638.00
est: -34.20 (-4,689.5%)
|
-1,685.10
est: -28.50 (-5,812.6%)
|
-21.60
est: -19.20 (-12.5%)
|
-26.40
est: -23.10 (-14.3%)
|
-28.80
est: -23.70 (-21.5%)
|
-13.50
est: -19.80 (+31.8%)
|
-6.27
est: -4.51 (-39.0%)
|
-4.16
-4.16 – -4.16
+7.8% YoY
|
-0.92
-0.92 – -0.92
+77.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-151.90B
OE per share TTM
-27,773.60
Owner's Yield
-1,305,284.21%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1,275,683.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
36
Total invested
2.26M
Insider transactions (90d)
1
Beneficial owners (>5%)
28
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2. | 16.78M | 12.00% | — | 16.78M | — | 16.78M | OO | Delaware | 2012-02-06 | ↗ |
| 2 | Advisors, LLC | 13.48M | 4.00% | — | 13.48M | — | — | OO | Delaware | 2011-10-13 | ↗ |
| 3 | Kopin | 13.48M | 4.00% | — | 13.48M | — | — | HC, IN | Delaware | 2011-10-13 | ↗ |
| 4 | Park West Asset Management LLC | 7.46M | 5.70% | 7.46M | — | 7.46M | — | IA | United States of America | 2015-11-02 | ↗ |
| 5 | Peter S. Park | 7.46M | 5.70% | 7.46M | — | 7.46M | — | IN | United States of America | 2015-11-02 | ↗ |
| 6 | 150837408 | 7.00M | 4.83% | — | 7.00M | — | 7.00M | CO | Cayman Islands | 2016-05-24 | ↗ |
| 7 | Park West Investors Master Fund, Limited | 6.57M | 5.00% | 6.57M | — | 6.57M | — | CO | United States of America | 2015-11-02 | ↗ |
| 8 | Israel A. Englander | 5.97M | 9.15% | — | 5.97M | — | 5.97M | IN | United States | 2004-05-13 | ↗ |
| 9 | Millennium Holding Group, L.P. | 5.97M | 9.15% | — | 5.97M | — | 5.97M | PN | Delaware | 2004-05-13 | ↗ |
| 10 | Millennium Management, LLC | 5.97M | 9.15% | — | 5.97M | — | 5.97M | OO | Delaware | 2004-05-13 | ↗ |
| 11 | The Riverview Group LLC | 5.97M | 9.15% | 5.97M | — | — | 5.97M | OO | Delaware | 2004-05-13 | ↗ |
| 12 | Beutel, Goodman & Company Ltd. | 5.59M | 6.57% | — | 4.25M | — | 4.25M | — | Delaware USA | 2013-10-11 | ↗ |
| 13 | MM Asset Management Inc. | 4.50M | 8.76% | — | — | — | — | CO | Cayman Islands | 2013-10-18 | ↗ |
| 14 | MMCAP International Inc. SPC | 4.50M | 8.76% | — | — | — | — | CO | Cayman Islands | 2013-10-18 | ↗ |
| 15 | Franklin Resources, Inc. | 3.64M | 6.90% | — | 2.48M | — | 2.48M | HC, CO | USA | 2014-01-28 | ↗ |
| 16 | SSGA FUNDS MANAGEMENT, INC. | 2.56M | 5.93% | — | 2.55M | — | 2.56M | IA | — | 2022-02-11 | ↗ |
| 17 | Genesee International, Inc. | 2.33M | 9.99% | — | 2.33M | — | 2.33M | CO | Delaware | 2002-01-29 | ↗ |
| 18 | Advantage Fund II Ltd. | 1.81M | 4.90% | — | 1.81M | — | 1.81M | CO | British Virgin Islands | 2003-11-12 | ↗ |
| 19 | Donald R. Morken | 1.81M | 4.90% | — | 1.81M | — | 1.81M | IN | Delaware | 2003-11-12 | ↗ |
| 20 | Genesee Investments LLC | 1.81M | 4.90% | — | 1.81M | — | 1.81M | CO | Delaware | 2003-11-12 | ↗ |
| 21 | Koch Investment Group Limited | 1.75M | 7.22% | 1.75M | — | 1.75M | — | CO | Delaware | 2001-10-01 | ↗ |
| 22 | (1) BlackRock, Inc. | 1.15M | 2.70% | 1.15M | — | 1.15M | — | HC | Delaware | 2022-07-08 | ↗ |
| 23 | STATE STREET CORPORATION | 980.3K | 2.27% | — | 889.1K | — | 980.3K | HC | BOSTON, MASSACHUSETTS | 2022-04-11 | ↗ |
| 24 | BAM Capital, LLC | 738.4K | 0.38% | — | 738.4K | — | — | OO | Delaware USA | 2010-01-06 | ↗ |
| 25 | BAM Management, LLC | 738.4K | 0.38% | — | 738.4K | — | — | OO | Delaware USA | 2010-01-06 | ↗ |
| 26 | BAM Opportunity Fund, L.P. | 738.4K | 0.38% | — | 738.4K | — | — | PN | Delaware USA | 2010-01-06 | ↗ |
| 27 | Hal Mintz | 738.4K | 0.38% | — | 738.4K | — | — | IN | Delaware USA | 2010-01-06 | ↗ |
| 28 | Ross Berman | 738.4K | 0.38% | — | 738.4K | — | — | IN | Delaware USA | 2010-01-06 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
36
-3 vs prev Q
New positions
5
Closed positions
8
Increased
15
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 285.1K -7.4K (-2.5%) | 1.50M -1.2M (-44.3%) | 3.56% -3.492 pp | 0.00% +0.000 pp | USD5.16 +1.9% | 3 qtrs — |
| 2 | MAI CAPITAL MANAGEMENT | 89.7K +12.9K (+16.7%) | 471.9K -235.2K (-33.3%) | 2.21% +0.361 pp | 0.00% -0.002 pp | USD3.97 +32.5% | 3 qtrs — |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 79.2K +18.4K (+30.3%) | 416.5K -142.4K (-25.5%) | 0.99% -0.476 pp | 0.00% +0.000 pp | USD6.17 -14.7% | 3 qtrs — |
| 4 | BLACKROCK, INC. | 43.3K -92.8K (-68.2%) | 227.6K -1.0M (-81.8%) | 0.54% -2.739 pp | 0.00% +0.000 pp | USD3.79 +38.8% | 3 qtrs — |
| 5 | BANK OF AMERICA CORP /DE/ | 41.0K +15.0 (+0.0%) | 215.6K -161.4K (-42.8%) | 0.51% -0.476 pp | 0.00% +0.000 pp | USD2.75 +91.3% | 3 qtrs — |
| 6 | STATE STREET CORP | 25.6K +2.3K (+9.9%) | 134.5K -79.6K (-37.2%) | 0.32% -0.242 pp | 0.00% +0.000 pp | USD8.85 -40.6% | 2 qtrs — |
| 7 | COMMONWEALTH EQUITY SERVICES, LLC | 21.7K -153.5K (-87.6%) | 114.0K -1.5M (-92.9%) | 0.27% -3.951 pp | 0.00% -0.002 pp | USD9.20 -42.8% | 2 qtrs — |
| 8 | NORTHERN TRUST CORP | 18.7K +4.5K (+31.6%) | 98.4K -32.3K (-24.7%) | 0.23% -0.109 pp | 0.00% +0.000 pp | USD8.25 -36.2% | 2 qtrs — |
| 9 | US BANCORP \DE\ | 18.4K +9.7K (+111.8%) | 96.9K +16.9K (+21.1%) | 0.23% +0.020 pp | 0.00% +0.000 pp | USD7.12 -26.1% | 2 qtrs — |
| 10 | ADVISOR GROUP HOLDINGS, INC. | 18.3K +986.0 (+5.7%) | 96.3K -57.7K (-37.5%) | 0.23% -0.189 pp | 0.00% 0.000 pp | USD2.89 +82.0% | 3 qtrs — |
| 11 | JANE STREET GROUP, LLC | 15.7K +15.7K (+100.0%) | 82.6K +82.6K (+100.0%) | 0.20% +0.196 pp | 0.00% +0.000 pp | USD5.26 +0.0% | 1 qtrs NEW |
| 12 | RENAISSANCE TECHNOLOGIES LLC | 15.4K +15.4K (+100.0%) | 81.0K +81.0K (+100.0%) | 0.19% +0.192 pp | 0.00% +0.000 pp | USD5.26 +0.0% | 1 qtrs NEW |
| 13 | UBS GROUP AG | 13.2K -2.3K (-15.0%) | 69.4K -73.4K (-51.4%) | 0.16% -0.209 pp | 0.00% +0.000 pp | USD2.75 +91.3% | 3 qtrs — |
| 14 | XTX TOPCO LTD | 12.5K +12.5K (+100.0%) | 65.8K +65.8K (+100.0%) | 0.16% +0.156 pp | 0.00% +0.002 pp | USD5.26 +0.0% | 1 qtrs NEW |
| 15 | CITADEL ADVISORS LLC | 11.8K +11.8K (+100.0%) | 62.1K +62.1K (+100.0%) | 0.15% +0.147 pp | 0.00% +0.000 pp | USD5.26 +0.0% | 1 qtrs NEW |
| 16 | HRT FINANCIAL LP | 11.5K +11.5K (+100.0%) | 60.0K +60.0K (+100.0%) | 0.14% +0.144 pp | 0.00% +0.000 pp | USD5.26 +0.0% | 1 qtrs NEW |
| 17 | HIGHTOWER ADVISORS, LLC | 10.0K +10.0K (+100.0%) | 52.6K +52.6K (+100.0%) | 0.25% +0.247 pp | 0.00% +0.000 pp | USD5.26 +0.0% | 1 qtrs NEW |
| 18 | CHILTON CAPITAL MANAGEMENT LLC | 5.2K +1.7K (+47.6%) | 27.4K -5.1K (-15.6%) | 0.13% +0.043 pp | 0.00% 0.000 pp | USD3.56 +47.8% | 3 qtrs — |
| 19 | JPMORGAN CHASE & CO | 1.7K +1.7K (+23,714.3%) | 8.8K +8.7K (+13,601.6%) | 0.04% +0.041 pp | 0.00% +0.000 pp | USD5.25 +0.2% | 3 qtrs — |
| 20 | ARCHER INVESTMENT CORP | 1.5K +— (+0.0%) | 7.9K -5.9K (-42.8%) | 0.02% -0.017 pp | 0.00% -0.001 pp | USD4.90 +7.3% | 3 qtrs — |
| 21 | WELLS FARGO & COMPANY/MN | 766.00 -11.0 (-1.4%) | 4.0K -3.1K (-43.6%) | 0.01% -0.009 pp | 0.00% +0.000 pp | USD2.75 +91.3% | 3 qtrs — |
| 22 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 686.00 +486.0 (+243.0%) | 3.6K +1.8K (+96.1%) | 0.01% +0.004 pp | 0.00% +0.000 pp | USD4.53 +16.1% | 3 qtrs — |
| 23 | — | 450.00 +450.0 (+100.0%) | 2.4K +2.4K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.001 pp | USD5.26 +0.0% | 1 qtrs NEW |
| 24 | TOWER RESEARCH CAPITAL LLC (TRC) | 364.00 -1.7K (-82.8%) | 1.9K -17.5K (-90.1%) | 0.00% -0.046 pp | 0.00% -0.001 pp | USD9.20 -42.8% | 2 qtrs — |
| 25 | ADVISORNET FINANCIAL, INC | 97.00 +— (+0.0%) | 510.00 -382.0 (-42.8%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD2.74 +92.0% | 3 qtrs — |
| 26 | FORTITUDE FAMILY OFFICE, LLC | 75.00 +75.0 (+100.0%) | 395.00 +395.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD5.25 +0.2% | 1 qtrs NEW |
| 27 | MORGAN STANLEY | 59.00 -414.0 (-87.5%) | 310.00 -4.0K (-92.9%) | 0.00% -0.011 pp | 0.00% +0.000 pp | USD2.75 +91.3% | 3 qtrs — |
| 28 | BNP PARIBAS ARBITRAGE, SNC | 41.00 -982.0 (-96.0%) | 216.00 -9.2K (-97.7%) | 0.00% -0.024 pp | 0.00% +0.000 pp | USD8.66 -39.3% | 3 qtrs — |
| 29 | ALERUS FINANCIAL NA | 38.00 +— (+0.0%) | 200.00 -150.0 (-42.9%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD9.18 -42.7% | 2 qtrs — |
| 30 | GABLES CAPITAL MANAGEMENT INC. | 26.00 +— (+0.0%) | 137.00 -102.0 (-42.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.73 +92.7% | 3 qtrs — |
| 31 | HUNTINGTON NATIONAL BANK | 16.00 +— (+0.0%) | 84.00 -64.0 (-43.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.69 +95.5% | 3 qtrs — |
| 32 | COMMUNITY BANK, N.A. | 16.00 +— (+0.0%) | 84.00 -63.0 (-42.9%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.75 +91.3% | 3 qtrs — |
| 33 | SBI SECURITIES CO., LTD. | 6.00 +— (+0.0%) | 32.00 -23.0 (-41.8%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.67 +97.0% | 3 qtrs — |
| 34 | SAGEVIEW ADVISORY GROUP, LLC | 6.00 +6.0 (+100.0%) | 32.00 +32.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.17 +1.7% | 1 qtrs NEW |
| 35 | ALLWORTH FINANCIAL LP | 4.00 +— (+0.0%) | 22.00 -15.0 (-40.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.75 +91.3% | 3 qtrs — |
| 36 | GOLDEN STATE WEALTH MANAGEMENT, LLC | 3.00 +— (+0.0%) | 16.00 -12.0 (-42.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.67 +97.0% | 3 qtrs — |
| 37 | PHYSICIAN WEALTH ADVISORS, INC. | 3.00 +— (+0.0%) | 16.00 -12.0 (-42.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.67 +97.0% | 3 qtrs — |
| 38 | NAVALIGN, LLC | 3.00 +3.0 (+100.0%) | 16.00 +16.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.00 +5.2% | 1 qtrs NEW |
| 39 | MARK SHEPTOFF FINANCIAL PLANNING, LLC | 1.00 +— (+0.0%) | 5.00 -4.0 (-44.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 +163.0% | 3 qtrs — |
| 40 | CITY STATE BANK | — -67.0 (-100.0%) | — -616.0 (-100.0%) | 0.00% -0.002 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 41 | DARWIN WEALTH MANAGEMENT, LLC | — -1.0 (-100.0%) | — -9.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 42 | GROUP ONE TRADING, L.P. | — -111.0 (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 43 | NEWEDGE ADVISORS, LLC | — -26.0 (-100.0%) | — -239.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 44 | ADVISORY SERVICES NETWORK, LLC | — -9.0 (-100.0%) | — -83.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 129.7K | 0.05% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 1.5K | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 4.1K | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 302.41 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 699.7K | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 1.5K | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 834.78 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 337.15 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 37.17 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 5.22 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
100.0K
Shares disposed
—
Cash buys
1.00
Cash sales
—
Net activity
+100,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | KERSTEN GEERT R | Director / Officer | P-Purchase | A | Common Stock | 100,000 | 1.19 | 119.0K | 222,497 | D | ↗ |
| 2026-03-31 | TALOR EYAL | Officer | A-Award | A | Common Stock | 747 | 3.21 | 2.4K | 7,011 | D | ↗ |
| 2026-03-31 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 1,336 | 3.21 | 4.3K | 13,364 | D | ↗ |
| 2026-03-31 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 1,682 | 3.21 | 5.4K | 122,497 | D | ↗ |
| 2026-01-22 | KERSTEN GEERT R | Director / Officer | P-Purchase | A | Common Stock | 38,023 | 5.26 | 200.0K | 120,815 | D | ↗ |
| 2025-12-31 | TALOR EYAL | Officer | A-Award | A | Common Stock | 456 | 5.26 | 2.4K | 6,264 | D | ↗ |
| 2025-12-31 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 815 | 5.26 | 4.3K | 12,028 | D | ↗ |
| 2025-12-31 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 998 | 5.26 | 5.2K | 82,792 | D | ↗ |
| 2025-12-04 | KERSTEN GEERT R | Director / Officer | P-Purchase | A | Common Stock | 8,389 | 5.96 | 50.0K | 81,794 | D | ↗ |
| 2025-09-30 | TALOR EYAL | Officer | A-Award | A | Common Stock | 260 | 9.20 | 2.4K | 5,808 | D | ↗ |
| 2025-09-30 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 466 | 9.20 | 4.3K | 11,213 | D | ↗ |
| 2025-09-30 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 570 | 9.20 | 5.2K | 73,405 | D | ↗ |
| 2025-07-28 | Watson Robert Eugene | Director | A-Award | A | Options | 4,000 | 8.20 | 32.8K | 27,266 | D | ↗ |
| 2025-07-28 | TALOR EYAL | Officer | A-Award | A | Options | 15,000 | 8.20 | 123.0K | 81,622 | D | ↗ |
| 2025-07-28 | PRICHEP PATRICIA B | Officer | A-Award | A | Options | 12,000 | 8.20 | 98.4K | 75,127 | D | ↗ |
| 2025-07-28 | KERSTEN GEERT R | Director / Officer | A-Award | A | Options | 25,000 | 8.20 | 205.0K | 175,157 | D | ↗ |
| 2025-07-28 | CIPRIANO JOHN | Officer | A-Award | A | Options | 7,500 | 8.20 | 61.5K | 38,008 | D | ↗ |
| 2025-07-28 | BAILLAVOINE BRUNO JEAN-MARIE | Director | A-Award | A | Options | 4,000 | 8.20 | 32.8K | 28,017 | D | ↗ |
| 2025-07-25 | Watson Robert Eugene | Director | P-Purchase | A | Common Stock | 2,919 | 6.85 | 20.0K | 3,733 | D | ↗ |
| 2025-07-25 | KERSTEN GEERT R | Director / Officer | P-Purchase | A | Common Stock | 29,197 | 6.85 | 200.0K | 72,835 | D | ↗ |
| 2025-06-30 | TALOR EYAL | Officer | A-Award | A | Common Stock | 1,048 | 2.29 | 2.4K | 5,548 | D | ↗ |
| 2025-06-30 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 1,873 | 2.29 | 4.3K | 10,747 | D | ↗ |
| 2025-06-30 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 2,292 | 2.29 | 5.2K | 43,638 | D | ↗ |
| 2025-03-31 | TALOR EYAL | Officer | A-Award | A | Common Stock | 10,416 | 0.23 | 2.4K | 135,013 | D | ↗ |
| 2025-03-31 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 15,432 | 0.23 | 3.6K | 266,230 | D | ↗ |
| 2025-03-31 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 22,786 | 0.23 | 5.2K | 1,240,378 | D | ↗ |
| 2024-06-28 | TALOR EYAL | Officer | A-Award | A | Common Stock | 2,068 | 1.16 | 2.4K | 116,332 | — | ↗ |
| 2024-06-28 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 3,698 | 1.16 | 4.3K | 236,024 | — | ↗ |
| 2024-06-28 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 4,461 | 1.16 | 5.2K | 1,199,770 | — | ↗ |
| 2024-05-08 | Watson Robert Eugene | Director | P-Purchase | A | Common Stock | 20,000 | 1.39 | 27.8K | 24,431 | — | ↗ |
| 2024-05-08 | PRICHEP PATRICIA B | Officer | P-Purchase | A | Common Stock | 8,000 | 1.39 | 11.1K | 232,326 | — | ↗ |
| 2024-05-08 | KERSTEN GEERT R | Director / Officer | P-Purchase | A | Common Stock | 30,000 | 1.39 | 41.7K | 1,195,309 | — | ↗ |
| 2024-04-19 | Watson Robert Eugene | Director | A-Award | A | Options | 64,000 | 1.50 | 96.0K | 698,000 | — | ↗ |
| 2024-04-19 | TALOR EYAL | Officer | A-Award | A | Options | 182,000 | 1.50 | 273.0K | 1,998,646 | — | ↗ |
| 2024-04-19 | PRICHEP PATRICIA B | Officer | A-Award | A | Options | 167,000 | 1.50 | 250.5K | 1,893,797 | — | ↗ |
| 2024-04-19 | KERSTEN GEERT R | Director / Officer | A-Award | A | Options | 250,000 | 1.50 | 375.0K | 4,504,709 | — | ↗ |
| 2024-04-19 | Gobbo Mario | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-04-19 | BAILLAVOINE BRUNO JEAN-MARIE | Director | A-Award | A | Options | 64,000 | 1.50 | 96.0K | 725,500 | — | ↗ |
| 2024-03-29 | TALOR EYAL | Officer | A-Award | A | Common Stock | 1,256 | 1.91 | 2.4K | 114,264 | — | ↗ |
| 2024-03-29 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 2,246 | 1.91 | 4.3K | 224,326 | — | ↗ |
| 2024-03-29 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 2,709 | 1.91 | 5.2K | 1,165,309 | — | ↗ |
| 2023-12-29 | TALOR EYAL | Officer | A-Award | A | Common Stock | 882 | 2.72 | 2.4K | 113,008 | — | ↗ |
| 2023-12-29 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 1,577 | 2.72 | 4.3K | 222,080 | — | ↗ |
| 2023-12-29 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 1,819 | 2.72 | 4.9K | 1,162,600 | — | ↗ |
| 2023-09-29 | TALOR EYAL | Officer | A-Award | A | Common Stock | 1,920 | 1.25 | 2.4K | 112,126 | — | ↗ |
| 2023-09-29 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 3,432 | 1.25 | 4.3K | 220,503 | — | ↗ |
| 2023-09-29 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 3,960 | 1.25 | 5.0K | 1,160,781 | — | ↗ |
| 2023-08-08 | YOUNG PETER R | Director | A-Award | A | Options | 64,000 | 1.36 | 87.0K | 667,300 | — | ↗ |
| 2023-08-08 | Watson Robert Eugene | Director | A-Award | A | Options | 64,000 | 1.36 | 87.0K | 634,000 | — | ↗ |
| 2023-08-08 | TALOR EYAL | Officer | A-Award | A | Options | 182,000 | 1.36 | 247.5K | 1,819,046 | — | ↗ |
| 2023-08-08 | PRICHEP PATRICIA B | Officer | A-Award | A | Options | 167,000 | 1.36 | 227.1K | 1,729,197 | — | ↗ |
| 2023-08-08 | Naughton Gail K | Director | A-Award | A | Options | 85,000 | 1.36 | 115.6K | 149,000 | — | ↗ |
| 2023-08-08 | KERSTEN GEERT R | Director / Officer | A-Award | A | Options | 250,000 | 1.36 | 340.0K | 4,258,309 | — | ↗ |
| 2023-08-08 | CIPRIANO JOHN | Officer | A-Award | A | Options | 65,000 | 1.36 | 88.4K | 917,027 | — | ↗ |
| 2023-08-08 | BAILLAVOINE BRUNO JEAN-MARIE | Director | A-Award | A | Options | 64,000 | 1.36 | 87.0K | 661,500 | — | ↗ |
| 2023-06-30 | TALOR EYAL | Officer | A-Award | A | Common Stock | 995 | 2.41 | 2.4K | 110,206 | — | ↗ |
| 2023-06-30 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 1,780 | 2.41 | 4.3K | 217,071 | — | ↗ |
| 2023-06-30 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 2,053 | 2.41 | 4.9K | 1,156,821 | — | ↗ |
| 2023-03-31 | TALOR EYAL | Officer | A-Award | A | Common Stock | 1,034 | 2.32 | 2.4K | 109,211 | — | ↗ |
| 2023-03-31 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 1,849 | 2.32 | 4.3K | 215,291 | — | ↗ |
| 2023-03-31 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 2,133 | 2.32 | 4.9K | 1,154,768 | — | ↗ |
| 2022-12-30 | TALOR EYAL | Officer | A-Award | A | Common Stock | 1,021 | 2.35 | 2.4K | 108,177 | — | ↗ |
| 2022-12-30 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 1,825 | 2.35 | 4.3K | 213,442 | — | ↗ |
| 2022-12-30 | KERSTEN GEERT R | Officer | A-Award | A | Common Stock | 1,851 | 2.35 | 4.3K | 1,152,635 | — | ↗ |
| 2022-09-30 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Common Stock | 1,266 | 3.09 | 3.9K | 120,226 | — | ↗ |
| 2022-09-30 | TALOR EYAL | Officer | A-Award | A | Common Stock | 776 | 3.09 | 2.4K | 107,156 | — | ↗ |
| 2022-09-30 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 1,388 | 3.09 | 4.3K | 211,617 | — | ↗ |
| 2022-09-30 | KERSTEN GEERT R | Officer | A-Award | A | Common Stock | 1,407 | 3.09 | 4.3K | 1,150,784 | — | ↗ |
| 2022-08-02 | Naughton Gail K | Director | — | D | Options | 64,000 | 3.61 | 231.0K | 0 | — | ↗ |
| 2022-06-30 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Common Stock | 876 | 4.50 | 3.9K | 118,960 | — | ↗ |
| 2022-06-30 | TALOR EYAL | Officer | A-Award | A | Common Stock | 533 | 4.50 | 2.4K | 106,380 | — | ↗ |
| 2022-06-30 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 953 | 4.50 | 4.3K | 210,229 | — | ↗ |
| 2022-06-30 | KERSTEN GEERT R | Officer | A-Award | A | Common Stock | 966 | 4.50 | 4.3K | 1,149,377 | — | ↗ |
| 2022-06-13 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Options | 80,000 | 0.01 | 800.00 | 832,353 | — | ↗ |
| 2022-06-13 | YOUNG PETER R | Director | A-Award | A | Options | 64,000 | 0.01 | 640.00 | 606,200 | — | ↗ |
| 2022-06-13 | Watson Robert Eugene | Director | A-Award | A | Options | 64,000 | 0.01 | 640.00 | 570,000 | — | ↗ |
| 2022-06-13 | TALOR EYAL | Officer | A-Award | A | Options | 182,000 | 3.35 | 609.7K | 1,644,246 | — | ↗ |
| 2022-06-13 | PRICHEP PATRICIA B | Officer | A-Award | A | Options | 167,000 | 3.35 | 559.5K | 1,569,397 | — | ↗ |
| 2022-06-13 | KERSTEN GEERT R | Officer | A-Award | A | Options | 250,000 | 0.01 | 2.5K | 4,030,109 | — | ↗ |
| 2022-06-13 | CIPRIANO JOHN | Officer | A-Award | A | Options | 65,000 | 0.01 | 650.00 | 852,927 | — | ↗ |
| 2022-06-13 | BAILLAVOINE BRUNO JEAN-MARIE | Director | A-Award | A | Options | 64,000 | 0.01 | 640.00 | 597,500 | — | ↗ |
| 2022-03-31 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Common Stock | 1,006 | 3.93 | 4.0K | 118,084 | — | ↗ |
| 2022-03-31 | TALOR EYAL | Officer | A-Award | A | Common Stock | 610 | 3.93 | 2.4K | 105,847 | — | ↗ |
| 2022-03-31 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 1,091 | 3.93 | 4.3K | 209,276 | — | ↗ |
| 2022-03-31 | KERSTEN GEERT R | Officer | A-Award | A | Common Stock | 1,106 | 3.93 | 4.3K | 1,148,411 | — | ↗ |
| 2021-12-31 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Common Stock | 557 | 7.10 | 4.0K | 117,078 | — | ↗ |
| 2021-12-31 | TALOR EYAL | Officer | A-Award | A | Common Stock | 338 | 7.10 | 2.4K | 105,237 | — | ↗ |
| 2021-12-31 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 604 | 7.10 | 4.3K | 208,185 | — | ↗ |
| 2021-12-31 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 612 | 7.10 | 4.3K | 1,147,305 | — | ↗ |
| 2021-11-19 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Options | 50,000 | 10.48 | 524.0K | 753,253 | — | ↗ |
| 2021-11-19 | TALOR EYAL | Officer | A-Award | A | Options | 50,000 | 10.48 | 524.0K | 1,463,446 | — | ↗ |
| 2021-11-19 | PRICHEP PATRICIA B | Officer | A-Award | A | Options | 50,000 | 10.48 | 524.0K | 1,403,597 | — | ↗ |
| 2021-11-19 | KERSTEN GEERT R | Director / Officer | A-Award | A | Options | 50,000 | 10.48 | 524.0K | 3,781,909 | — | ↗ |
| 2021-11-19 | CIPRIANO JOHN | Officer | A-Award | A | Options | 50,000 | 10.48 | 524.0K | 788,827 | — | ↗ |
| 2021-10-19 | TALOR EYAL | Officer | S-Sale | D | Common Stock | 15,000 | 11.25 | 168.8K | 104,899 | — | ↗ |
| 2021-09-30 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Common Stock | 343 | 10.99 | 3.8K | 116,521 | — | ↗ |
| 2021-09-30 | TALOR EYAL | Officer | A-Award | A | Common Stock | 218 | 10.99 | 2.4K | 119,899 | — | ↗ |
| 2021-09-30 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 372 | 10.99 | 4.1K | 207,581 | — | ↗ |
| 2021-09-30 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 395 | 10.99 | 4.3K | 1,146,693 | — | ↗ |
| 2021-07-06 | Watson Robert Eugene | Director | P-Purchase | A | Common Stock | 1,250 | 8.00 | 10.0K | 4,431 | — | ↗ |
| 2021-07-06 | KERSTEN GEERT R | Director / Officer | P-Purchase | A | Common Stock | 25,000 | 8.00 | 200.0K | 1,146,298 | — | ↗ |
| 2021-07-06 | BAILLAVOINE BRUNO JEAN-MARIE | Director | P-Purchase | A | Common Stock | 1,250 | 8.00 | 10.0K | 5,973 | — | ↗ |
| 2021-06-30 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Common Stock | 435 | 8.68 | 3.8K | 116,178 | — | ↗ |
| 2021-06-30 | TALOR EYAL | Officer | A-Award | A | Common Stock | 276 | 8.68 | 2.4K | 119,681 | — | ↗ |
| 2021-06-30 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 471 | 8.68 | 4.1K | 207,209 | — | ↗ |
| 2021-06-30 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 501 | 8.68 | 4.3K | 1,121,298 | — | ↗ |
| 2021-06-28 | YOUNG PETER R | Director | P-Purchase | A | Common Stock | 3,000 | 12.66 | 38.0K | 28,914 | — | ↗ |
| 2021-05-14 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Options | 160,000 | 20.61 | 3.30M | 703,253 | — | ↗ |
| 2021-05-14 | YOUNG PETER R | Director | A-Award | A | Options | 128,000 | 20.61 | 2.64M | 543,100 | — | ↗ |
| 2021-05-14 | Watson Robert Eugene | Director | A-Award | A | Options | 128,000 | 20.61 | 2.64M | 506,000 | — | ↗ |
| 2021-05-14 | TALOR EYAL | Officer | A-Award | A | Options | 318,000 | 20.61 | 6.55M | 1,413,446 | — | ↗ |
| 2021-05-14 | PRICHEP PATRICIA B | Officer | A-Award | A | Options | 288,000 | 20.61 | 5.94M | 1,353,597 | — | ↗ |
| 2021-05-14 | KERSTEN GEERT R | Director / Officer | A-Award | A | Options | 592,000 | 20.61 | 12.20M | 3,731,909 | — | ↗ |
| 2021-05-14 | CIPRIANO JOHN | Officer | A-Award | A | Options | 130,000 | 20.61 | 2.68M | 738,827 | — | ↗ |
| 2021-05-14 | BAILLAVOINE BRUNO JEAN-MARIE | Director | A-Award | A | Options | 128,000 | 20.61 | 2.64M | 533,500 | — | ↗ |
| 2021-04-22 | CIPRIANO JOHN | Officer | S-Sale | D | Common Stock | 10,000 | 24.38 | 243.8K | 63,108 | — | ↗ |
| 2021-03-31 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Common Stock | 248 | 15.21 | 3.8K | 115,743 | — | ↗ |
| 2021-03-31 | TALOR EYAL | Officer | A-Award | A | Common Stock | 157 | 15.21 | 2.4K | 119,405 | — | ↗ |
| 2021-03-31 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 269 | 15.21 | 4.1K | 206,738 | — | ↗ |
| 2021-03-31 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 285 | 15.21 | 4.3K | 1,120,797 | — | ↗ |
| 2020-12-31 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Common Stock | 309 | 11.66 | 3.6K | 115,495 | — | ↗ |
| 2020-12-31 | TALOR EYAL | Officer | A-Award | A | Common Stock | 205 | 11.66 | 2.4K | 119,248 | — | ↗ |
| 2020-12-31 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 335 | 11.66 | 3.9K | 206,469 | — | ↗ |
| 2020-12-31 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 366 | 11.66 | 4.3K | 1,120,512 | — | ↗ |
| 2020-12-11 | YOUNG PETER R | Director | P-Purchase | A | Common Stock | 100 | 14.24 | 1.4K | 25,914 | — | ↗ |
| 2020-11-18 | Watson Robert Eugene | Director | P-Purchase | A | Common Stock | 800 | 11.77 | 9.4K | 3,181 | — | ↗ |
| 2020-11-18 | BAILLAVOINE BRUNO JEAN-MARIE | Director | P-Purchase | A | Common Stock | 800 | 11.77 | 9.4K | 4,723 | — | ↗ |
| 2020-11-17 | YOUNG PETER R | Director | P-Purchase | A | Common Stock | 800 | 11.68 | 9.3K | 25,814 | — | ↗ |
| 2020-11-13 | CIPRIANO JOHN | Officer | S-Sale | D | Common Stock | 10,000 | 12.73 | 127.3K | 73,108 | — | ↗ |
| 2020-11-04 | YOUNG PETER R | Director | P-Purchase | A | Common Stock | 1,000 | 11.39 | 11.4K | 23,014 | — | ↗ |
| 2020-09-30 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Common Stock | 275 | 12.75 | 3.5K | 115,186 | — | ↗ |
| 2020-09-30 | TALOR EYAL | Officer | A-Award | A | Common Stock | 188 | 12.75 | 2.4K | 119,043 | — | ↗ |
| 2020-09-30 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 297 | 12.75 | 3.8K | 206,134 | — | ↗ |
| 2020-09-30 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 335 | 12.75 | 4.3K | 1,120,146 | — | ↗ |
| 2020-06-30 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Common Stock | 228 | 14.92 | 3.4K | 114,911 | — | ↗ |
| 2020-06-30 | TALOR EYAL | Officer | A-Award | A | Common Stock | 160 | 14.92 | 2.4K | 118,855 | — | ↗ |
| 2020-06-30 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 245 | 14.92 | 3.7K | 205,837 | — | ↗ |
| 2020-06-30 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 286 | 14.92 | 4.3K | 1,119,811 | — | ↗ |
| 2020-04-20 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Options | 160,000 | 10.93 | 1.75M | 544,453 | — | ↗ |
| 2020-04-20 | YOUNG PETER R | Director | A-Award | A | Options | 128,000 | 10.93 | 1.40M | 416,300 | — | ↗ |
| 2020-04-20 | Watson Robert Eugene | Director | A-Award | A | Options | 128,000 | 10.93 | 1.40M | 378,000 | — | ↗ |
| 2020-04-20 | TALOR EYAL | Officer | A-Award | A | Options | 288,000 | 10.93 | 3.15M | 1,096,646 | — | ↗ |
| 2020-04-20 | PRICHEP PATRICIA B | Officer | A-Award | A | Options | 288,000 | 10.93 | 3.15M | 1,066,797 | — | ↗ |
| 2020-04-20 | KERSTEN GEERT R | Director / Officer | A-Award | A | Options | 592,000 | 10.93 | 6.47M | 3,142,309 | — | ↗ |
| 2020-04-20 | CIPRIANO JOHN | Officer | A-Award | A | Options | 160,000 | 10.93 | 1.75M | 610,027 | — | ↗ |
| 2020-04-20 | BAILLAVOINE BRUNO JEAN-MARIE | Director | A-Award | A | Options | 128,000 | 10.93 | 1.40M | 405,500 | — | ↗ |
| 2020-03-31 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Common Stock | 296 | 11.54 | 3.4K | 114,683 | — | ↗ |
| 2020-03-31 | TALOR EYAL | Officer | A-Award | A | Common Stock | 207 | 11.54 | 2.4K | 118,695 | — | ↗ |
| 2020-03-31 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 317 | 11.54 | 3.7K | 205,592 | — | ↗ |
| 2020-03-31 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 370 | 11.54 | 4.3K | 1,119,525 | — | ↗ |
| 2020-02-26 | ZIMMERMAN DANIEL H | Officer | P-Purchase | A | Common Stock | 923 | 10.83 | 10.0K | 114,387 | — | ↗ |
| 2020-02-26 | YOUNG PETER R | Director | P-Purchase | A | Common Stock | 923 | 10.83 | 10.0K | 22,014 | — | ↗ |
| 2020-02-26 | Watson Robert Eugene | Director | P-Purchase | A | Common Stock | 923 | 10.83 | 10.0K | 2,381 | — | ↗ |
| 2020-02-26 | PRICHEP PATRICIA B | Officer | P-Purchase | A | Common Stock | 1,847 | 10.83 | 20.0K | 205,275 | — | ↗ |
| 2020-02-26 | KERSTEN GEERT R | Director / Officer | P-Purchase | A | Common Stock | 4,617 | 10.83 | 50.0K | 1,119,155 | — | ↗ |
| 2020-02-26 | BAILLAVOINE BRUNO JEAN-MARIE | Director | P-Purchase | A | Common Stock | 923 | 10.83 | 10.0K | 3,923 | — | ↗ |
| 2020-01-10 | KERSTEN GEERT R | Director / Officer | P-Purchase | A | Common Stock | 6,631 | 7.54 | 50.0K | 1,114,538 | — | ↗ |
| 2019-12-31 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Common Stock | 373 | 9.15 | 3.4K | 113,464 | — | ↗ |
| 2019-12-31 | TALOR EYAL | Officer | A-Award | A | Common Stock | 262 | 9.15 | 2.4K | 118,488 | — | ↗ |
| 2019-12-31 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 401 | 9.15 | 3.7K | 203,428 | — | ↗ |
| 2019-12-31 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 483 | 9.15 | 4.4K | 1,107,907 | — | ↗ |
| 2019-10-25 | KERSTEN GEERT R | Director / Officer | P-Purchase | A | Common Stock | 3,725 | 6.71 | 25.0K | 1,107,424 | — | ↗ |
| 2019-09-30 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Common Stock | 382 | 8.94 | 3.4K | 113,091 | — | ↗ |
| 2019-09-30 | TALOR EYAL | Officer | A-Award | A | Common Stock | 268 | 8.94 | 2.4K | 118,226 | — | ↗ |
| 2019-09-30 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 410 | 8.94 | 3.7K | 203,027 | — | ↗ |
| 2019-09-30 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 461 | 8.94 | 4.1K | 1,103,699 | — | ↗ |
| 2019-09-17 | CIPRIANO JOHN | Officer | S-Sale | D | Common Stock | 8,000 | 8.69 | 69.6K | 83,108 | — | ↗ |
| 2019-09-04 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Common Stock | 2,375 | 7.16 | 17.0K | 112,302 | — | ↗ |
| 2019-09-04 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 2,095 | 7.16 | 15.0K | 202,180 | — | ↗ |
| 2019-09-04 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 3,492 | 7.16 | 25.0K | 1,102,746 | — | ↗ |
| 2019-08-28 | CIPRIANO JOHN | Officer | S-Sale | D | Common Stock | 8,000 | 7.03 | 56.2K | 91,108 | — | ↗ |
| 2019-06-03 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 6,631 | 3.77 | 25.0K | 1,099,254 | — | ↗ |
| 2019-05-21 | YOUNG PETER R | Director | P-Purchase | A | Common Stock | 2,000 | 5.00 | 10.0K | 21,091 | — | ↗ |
| 2019-05-07 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Common Stock | 4,373 | 6.86 | 30.0K | 109,927 | — | ↗ |
| 2019-05-07 | Watson Robert Eugene | Director | A-Award | A | Common Stock | 1,458 | 6.86 | 10.0K | 1,458 | — | ↗ |
| 2019-05-07 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 7,289 | 6.86 | 50.0K | 200,085 | — | ↗ |
| 2019-05-07 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 14,577 | 6.86 | 100.0K | 1,092,623 | — | ↗ |
| 2019-05-07 | CIPRIANO JOHN | Officer | A-Award | A | Common Stock | 2,915 | 6.86 | 20.0K | 99,108 | — | ↗ |
| 2019-04-11 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Options | 211,459 | 5.65 | 1.19M | 384,453 | — | ↗ |
| 2019-04-11 | YOUNG PETER R | Director | A-Award | A | Options | 160,000 | 5.65 | 904.0K | 289,200 | — | ↗ |
| 2019-04-11 | Watson Robert Eugene | Director | A-Award | A | Options | 160,000 | 5.65 | 904.0K | 250,000 | — | ↗ |
| 2019-04-11 | TALOR EYAL | Officer | A-Award | A | Options | 382,712 | 5.65 | 2.16M | 822,209 | — | ↗ |
| 2019-04-11 | PRICHEP PATRICIA B | Officer | A-Award | A | Options | 405,631 | 5.65 | 2.29M | 794,265 | — | ↗ |
| 2019-04-11 | KERSTEN GEERT R | Director / Officer | A-Award | A | Options | 813,180 | 5.65 | 4.59M | 2,574,863 | — | ↗ |
| 2019-04-11 | CIPRIANO JOHN | Officer | A-Award | A | Options | 206,880 | 5.65 | 1.17M | 450,427 | — | ↗ |
| 2019-04-11 | BAILLAVOINE BRUNO JEAN-MARIE | Director | A-Award | A | Options | 160,000 | 5.65 | 904.0K | 277,500 | — | ↗ |
| 2019-04-05 | YOUNG PETER R | Director | P-Purchase | A | Common Stock | 2,000 | 5.20 | 10.4K | 19,091 | — | ↗ |
| 2019-03-29 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Common Stock | 965 | 3.54 | 3.4K | 105,554 | — | ↗ |
| 2019-03-29 | TALOR EYAL | Officer | A-Award | A | Common Stock | 677 | 3.54 | 2.4K | 117,672 | — | ↗ |
| 2019-03-29 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 1,036 | 3.54 | 3.7K | 192,796 | — | ↗ |
| 2019-03-29 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 1,165 | 3.54 | 4.1K | 1,078,046 | — | ↗ |
| 2019-02-14 | YOUNG PETER R | Director | P-Purchase | A | Common Stock | 1,000 | 2.82 | 2.8K | 17,091 | — | ↗ |
| 2018-12-31 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Common Stock | 1,190 | 2.87 | 3.4K | 107,063 | — | ↗ |
| 2018-12-31 | TALOR EYAL | Officer | A-Award | A | Common Stock | 836 | 2.87 | 2.4K | 116,995 | — | ↗ |
| 2018-12-31 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 1,278 | 2.87 | 3.7K | 191,760 | — | ↗ |
| 2018-12-31 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 1,437 | 2.87 | 4.1K | 1,076,881 | — | ↗ |
| 2018-09-28 | ZIMMERMAN DANIEL H | Officer | A-Award | A | Common Stock | 843 | 4.05 | 3.4K | 105,873 | — | ↗ |
| 2018-09-28 | TALOR EYAL | Officer | A-Award | A | Common Stock | 592 | 4.05 | 2.4K | 116,159 | — | ↗ |
| 2018-09-28 | PRICHEP PATRICIA B | Officer | A-Award | A | Common Stock | 906 | 4.05 | 3.7K | 190,482 | — | ↗ |
| 2018-09-28 | KERSTEN GEERT R | Director / Officer | A-Award | A | Common Stock | 1,018 | 4.05 | 4.1K | 1,075,444 | — | ↗ |
Executive team
Top executives
Shares Outstanding
6.87M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Geert R. Kersten, Chief Executive and Financial Officer and Treasurer | 644.1K | — | 20.5K | 340.4K | — | 65.6K | 1.07M | 33.71% | ↗ |
| 2 | 2024 | Eyal Talor, Ph.D., Chief Scientific Officer | 349.6K | — | 9.6K | 247.8K | — | 6.0K | 613.0K | 41.99% | ↗ |
| 3 | 2024 | Patricia B. Prichep, Senior Vice President of Operations and Secretary | 289.2K | — | 17.2K | 227.4K | — | 9.0K | 542.7K | 45.05% | ↗ |
| 4 | 2024 | John Cipriano Senior Vice President of Regulatory Affairs | 249.6K | — | — | — | — | 31.00 | 249.6K | 0.00% | ↗ |
| 5 | 2023 | Geert R. Kersten, Chief Executive and Financial Officer and Treasurer | 637.2K | — | 19.2K | 306.0K | — | 65.6K | 1.03M | 31.63% | ↗ |
| 6 | 2023 | Eyal Talor, Ph.D., Chief Scientific Officer | 345.8K | — | 9.6K | 222.8K | — | 6.0K | 584.2K | 39.77% | ↗ |
| 7 | 2023 | Patricia B. Prichep, Senior Vice President of Operations and Secretary | 286.1K | — | 17.2K | 204.4K | — | 9.0K | 516.7K | 42.88% | ↗ |
| 8 | 2023 | John Cipriano Senior Vice President of Regulatory Affairs | 246.9K | — | — | 79.6K | — | 31.00 | 326.5K | 24.36% | ↗ |
| 9 | 2023 | John Cipriano, Senior Vice President of Regulatory Affairs | 246.9K | — | — | 79.6K | — | 31.00 | 326.5K | 24.36% | ↗ |
| 10 | 2023 | Daniel Zimmerman, Ph.D., Senior Vice President of Research, Cellular Immunology | 45.5K | — | — | — | — | 531.00 | 46.1K | 0.00% | ↗ |
| 11 | 2022 | Geert R. Kersten, Chief Executive and Financial Officer and Treasurer | 616.4K | — | 17.4K | 748.5K | — | 55.6K | 1.44M | 53.26% | ↗ |
| 12 | 2022 | Eyal Talor, Ph.D., Chief Scientific Officer | 334.6K | — | 9.6K | 544.9K | — | 6.0K | 895.1K | 61.95% | ↗ |
| 13 | 2022 | Patricia B. Prichep, Senior Vice President of Operations and Secretary | 277.0K | — | 17.2K | 500.0K | — | 9.0K | 803.2K | 64.39% | ↗ |
| 14 | 2022 | Patricia B. Prichep, Senior Vice President of Operations and Corporate Secretary | 277.0K | — | 17.2K | 500.0K | — | 9.0K | 803.2K | 64.39% | ↗ |
| 15 | 2022 | Daniel Zimmerman, Ph.D., Senior Vice President of Research, Cellular Immunology | 256.8K | — | 15.8K | 239.5K | — | 6.0K | 518.1K | 49.27% | ↗ |
| 16 | 2022 | John Cipriano, Senior Vice President of Regulatory Affairs | 239.1K | — | — | 194.6K | — | 31.00 | 433.7K | 44.87% | ↗ |
| 17 | 2021 | Geert R. Kersten, Chief Executive and Financial Officer and Treasurer | 580.0K | — | 17.3K | 201.3K | — | 55.6K | 854.3K | 25.59% | ↗ |
| 18 | 2021 | Eyal Talor, Ph.D., Chief Scientific Officer | 314.8K | — | 9.6K | 97.9K | — | 6.0K | 428.4K | 25.10% | ↗ |
| 19 | 2021 | Patricia B. Prichep, Senior Vice President of Operations and Corporate Secretary | 261.0K | — | 16.2K | 97.9K | — | 9.0K | 384.2K | 29.71% | ↗ |
| 20 | 2021 | Daniel Zimmerman, Ph.D., Senior Vice President of Research, Cellular Immunology | 243.0K | — | 14.9K | 54.4K | — | 6.0K | 318.3K | 21.78% | ↗ |
| 21 | 2021 | John Cipriano, Senior Vice President of Regulatory Affairs | 225.3K | — | — | 54.4K | — | 31.00 | 279.8K | 19.44% | ↗ |
| 22 | 2020 | Geert R. Kersten, Chief Executive and Financial Officer and Treasurer | 756.1K | 13.8K | 17.3K | 2.49M | — | 55.6K | 3.34M | 75.25% | ↗ |
| 23 | 2020 | Geert R. Kersten, Chief Executive and Financial Officer | 756.1K | 13.8K | 17.3K | 2.49M | — | 55.6K | 3.34M | 75.25% | ↗ |
| 24 | 2020 | Patricia B. Prichep, Senior Vice President | 366.7K | 7.6K | 14.8K | 1.21M | — | 9.0K | 1.61M | 76.20% | ↗ |
| 25 | 2020 | Patricia B. Prichep, Senior Vice President of Operations and Corporate Secretary | 366.7K | 7.6K | 14.8K | 1.21M | — | 9.0K | 1.61M | 76.20% | ↗ |
| 26 | 2020 | Eyal Talor, Ph.D., Chief Scientific Officer | 308.3K | 3.2K | 9.6K | 1.21M | — | 6.0K | 1.54M | 79.38% | ↗ |
| 27 | 2020 | Daniel Zimmerman, Ph.D., Senior Vice President of Research, Cellular Immunology | 239.6K | 2.9K | 13.8K | 673.6K | — | 6.0K | 935.9K | 73.44% | ↗ |
| 28 | 2020 | John Cipriano, Senior Vice President of Regulatory Affairs | 235.2K | 1.8K | — | 673.6K | — | 31.00 | 910.6K | 73.97% | ↗ |
| 29 | 2019 | Geert R. Kersten, Chief Executive | 511.4K | — | 16.5K | 3.92M | — | 55.6K | 4.51M | 87.42% | ↗ |
| 30 | 2019 | Geert R. Kersten, Chief Executive and Financial Officer | 511.4K | — | 16.5K | 3.92M | — | 55.6K | 4.51M | 87.42% | ↗ |
| 31 | 2019 | Patricia B. Prichep, Senior Vice President | 286.0K | — | 14.7K | 1.96M | — | 9.0K | 2.27M | 86.98% | ↗ |
| 32 | 2019 | Eyal Talor, Ph.D., Chief Scientific Officer | 370.4K | — | 9.6K | 1.85M | — | 6.0K | 2.23M | 83.14% | ↗ |
| 33 | 2019 | Daniel Zimmerman, Ph.D., Senior Vice President of Research, Cellular | 243.6K | — | 13.7K | 1.02M | — | 6.0K | 1.28M | 80.55% | ↗ |
| 34 | 2019 | John Cipriano, Senior Vice President of Regulatory Affairs | 202.7K | — | — | 998.0K | — | 31.00 | 1.20M | 83.12% | ↗ |
| 35 | 2018 | Geert R. Kersten, Chief Executive | 557.8K | — | 16.4K | 1.01M | — | 55.6K | 1.64M | 62.62% | ↗ |
| 36 | 2018 | Eyal Talor, Ph.D., Chief Scientific Officer | 264.9K | — | 9.6K | 681.4K | — | 6.0K | 961.9K | 71.83% | ↗ |
| 37 | 2018 | Patricia B. Prichep, Senior Vice President | 162.4K | — | 14.7K | 424.6K | — | 9.0K | 610.6K | 71.93% | ↗ |
| 38 | 2018 | Daniel Zimmerman, Ph.D., Senior Vice President of Research, Cellular | 276.2K | — | 13.7K | 240.7K | — | 6.0K | 536.5K | 47.40% | ↗ |
| 39 | 2018 | John Cipriano, Senior Vice President of Regulatory Affairs | 234.2K | — | — | 282.9K | — | 31.00 | 517.2K | 54.71% | ↗ |
| 40 | 2017 | Geert R. Kersten, Chief Executive Officer and Treasurer | 437.5K | — | 15.9K | 327.0K | — | 55.6K | 836.0K | 41.01% | ↗ |
| 41 | 2017 | Geert R. Kersten, Chief Executive | 437.5K | — | 15.9K | 327.0K | — | 55.6K | 836.0K | 41.01% | ↗ |
| 42 | 2017 | Eyal Talor, Ph.D., Chief Scientific Officer xcxcxc | 270.2K | — | 9.6K | 218.0K | — | 6.0K | 503.8K | 45.17% | ↗ |
| 43 | 2017 | Eyal Talor, Ph.D., Chief Scientific Officer | 270.2K | — | 9.6K | 218.0K | — | 6.0K | 503.8K | 45.17% | ↗ |
| 44 | 2017 | Patricia B. Prichep, Senior Vice President | 171.0K | — | 13.7K | 218.0K | — | 9.0K | 411.7K | 56.27% | ↗ |
| 45 | 2017 | Patricia B. Prichep, Senior Vice President of Operations and | 171.0K | — | 13.7K | 218.0K | — | 9.0K | 411.7K | 56.27% | ↗ |
| 46 | 2017 | John Cipriano, Senior Vice President of Regulatory Affairs | 185.6K | — | — | 163.5K | — | 31.00 | 349.1K | 46.83% | ↗ |
| 47 | 2017 | Daniel Zimmerman, Ph.D., Senior Vice President of Research, Cellular | 166.3K | — | 13.3K | 36.0K | — | 6.0K | 221.7K | 22.25% | ↗ |
| 48 | 2016 | Geert R. Kersten, Chief Executive Officer and Treasurer | 558.4K | — | 15.9K | — | — | 55.0K | 629.3K | 2.53% | ↗ |
| 49 | 2016 | Eyal Talor, Ph.D., Chief Scientific Officer xcxcxc | 303.6K | — | 9.6K | — | — | 6.0K | 319.2K | 3.01% | ↗ |
| 50 | 2016 | Daniel Zimmerman, Ph.D., Senior Vice President of Research, Cellular | 228.4K | — | 13.7K | 37.1K | — | 6.0K | 285.2K | 17.81% | ↗ |
| 51 | 2016 | Patricia B. Prichep, Senior Vice President of Operations and | 245.8K | — | 14.7K | — | — | 9.0K | 269.6K | 5.46% | ↗ |
| 52 | 2016 | John Cipriano, Senior Vice President of Regulatory Affairs | 211.4K | — | — | — | — | 31.00 | 211.4K | 0.00% | ↗ |
| 53 | 2015 | Geert R. Kersten, Chief Executive Officer and Treasurer | 514.1K | — | 16.1K | — | — | 55.0K | 585.1K | 2.74% | ↗ |
| 54 | 2015 | Eyal Talor, Ph.D., Chief Scientific Officer xcxcxc | 291.0K | — | 9.6K | — | — | 6.0K | 306.6K | 3.13% | ↗ |
| 55 | 2015 | Daniel Zimmerman, Ph.D., Senior Vice President of Research, Cellular | 219.0K | — | 13.1K | 52.0K | — | 6.0K | 290.2K | 22.45% | ↗ |
| 56 | 2015 | Patricia B. Prichep, Senior Vice President of Operations and | 235.7K | — | 14.1K | — | — | 6.9K | 256.7K | 5.50% | ↗ |
| 57 | 2015 | John Cipriano, Senior Vice President of Regulatory Affairs | 202.7K | — | — | — | — | 31.00 | 202.7K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Geert R. Kersten | Chief Executive & Financial Officer, CAO,Treasurer and Director | 709.7K | male |
| Eyal Talor | Chief Scientific Officer | 355.6K | — |
| Patricia Prichep | Chief Financial & Operations Officer, Compliance Officer & Corporate Secretary | 298.2K | female |
| John Cipriano | Senior Vice President of Regulatory Affairs | 249.6K | male |
| Giovanni Selvaggi | Acting Chief Medical Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CVM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
